AUTEK(SZ:300595)2024-08-16 23:52Group 1: Company Performance - The company reported a revenue increase of over 25% in its optical service business, which now accounts for more than 52% of total revenue [4] - The sales of frame glasses and other optical products reached 161 million CNY, reflecting a growth of 44% [5] - The company has added over 470 optical service terminals, with terminal business revenue also growing over 25% [4] Group 2: Product Development and Market Strategy - The company is currently conducting Phase III clinical trials for low-concentration atropine eye drops, with enrollment ongoing [3] - The sales of orthokeratology lenses have shown fluctuations, with a weaker second quarter compared to the first [3] - The company remains optimistic about the long-term prospects of orthokeratology lenses, citing unique benefits such as allowing users to not wear glasses during the day [3] Group 3: Competitive Landscape - The orthokeratology lens market faces challenges due to high-end consumer fatigue and increased competition from various myopia control products [5] - Despite current growth challenges, the company believes that orthokeratology lenses will remain a preferred choice due to their proven effectiveness and user satisfaction [5] Group 4: Investor Relations and Communication - The company held an online investor meeting to address questions regarding its semi-annual report and to understand investor concerns [6] - The management team emphasized their commitment to a comprehensive optical product and service strategy, adapting to macroeconomic conditions [6]